Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Parexel Intl Cp (PRXL)

Parexel Intl Cp (PRXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Parexel Intl Cp 195 WEST ST WALTHAM MA 02451 USA

www.parexel.com P: 781-487-9900

Description:

Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales.

Key Statistics

Overview:

Market Capitalization, $K 4,502,650
Shares Outstanding, K 51,120
Annual Sales, $ 2,442 M
Annual Net Income, $ 107,300 K
Last Quarter Sales, $ 647,600 K
Last Quarter Net Income, $ 29,900 K
60-Month Beta 0.79
% of Insider Shareholders 2.90%
% of Institutional Shareholders 87.45%

Growth:

1-Year Return 28.58%
3-Year Return 40.91%
5-Year Return 176.89%
5-Year Revenue Growth 50.87%
5-Year Earnings Growth 201.82%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.74 on 05/03/17
Next Earnings Date 10/25/17
Earnings Per Share ttm 3.37
EPS Growth vs. Prev Qtr 37.84%
EPS Growth vs. Prev Year 8.51%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 03/04/08

PRXL Ratios

Ratio
Price/Earnings ttm 26.14
Price/Earnings forward 22.91
Price/Earnings to Growth 1.76
Return-on-Equity % 28.98%
Return-on-Assets % 7.94%
Profit Margin % 4.39%
Debt/Equity 1.01
Price/Sales 1.84
Price/Cash Flow 16.08
Price/Book 7.09
Book Value/Share 12.42
Interest Coverage 12.11
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar